Moveable walls and a stunning number of robotics at its sites in France and Singapore, among other features, has earned Sanofi international recognition for innovation.
- Prevascularized Bio-hybrid Organ Platforms Are Redefining Cell Therapy Delivery
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Can A Biotech Create A CDMO Market?
- Why Are Life Science Companies So Poorly Prepared For RIM's Future?
- April 2026 — CDMO Opportunities And Threats Report
- Cell And Gene Therapies: The Emerging Reality For Scalable Market Readiness
- Tackling The Cell & Gene Therapy Sector's Practical Post-Approval Problem
- Why Your MES RFP Is Failing Before It Starts
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-2190246741 lab]( "Phase-Appropriate Approaches To Manufacturing And Testing")
Phase-Appropriate Approaches To Manufacturing And TestingAccelerate the development of high-quality biopharmaceuticals by implementing phase-appropriate, risk-based manufacturing and testing strategies that ensure timely progression.
-
![GettyImages-2193981966-dna-helix-built-molecule]( "Rapidly Assess Drug Response In 2D And 3D Breast Cancer Model Systems")
Rapidly Assess Drug Response In 2D And 3D Breast Cancer Model SystemsFor years, 2D cell cultures have been crucial in drug discovery. Explore how 3D cultures offer more biologically relevant models today that enhance cancer research and drug efficacy assessments.
-
![GettyImages-1413755087-business-man-computer-data-workflow-automation]( "Accelerating Clinical Data Review With Traceable Workflows")
Accelerating Clinical Data Review With Traceable WorkflowsClinical data review needs centralized access and traceable workflows. Leveraging AI-automation and real-time collaboration drives faster, better-informed decisions and reduced compliance risk.
-
![Lonza Nucleofector]( "Non-Viral Genetic Modification Using The 4D-Nucleofector LV Unit In CGT")
Non-Viral Genetic Modification Using The 4D-Nucleofector LV Unit In CGTThis paper underscores the 4D-Nucleofector® LV Unit as a pivotal tool for translating genetic modification technologies into scalable, safe, and effective therapeutic solutions.
-
![GettyImages-2155672333-2025-road-future-looking]( "Future-Proofing Life Sciences Manufacturing: 2025 CDMO Trends")
Future-Proofing Life Sciences Manufacturing: 2025 CDMO TrendsReview contract manufacturing's evolution, driven by technological advancements and regulatory changes, and how CMOs and CDMOs are navigating opportunities and challenges.
-
![Pharmaceutical bioreactor-GettyImages-836094936]( "Expansion Of Cord Blood-Derived CD34+ Cells In A Hollow-Fiber Bioreactor With 10% Standard Cytokine Concentration")
Expansion Of Cord Blood-Derived CD34+ Cells In A Hollow-Fiber Bioreactor With 10% Standard Cytokine ConcentrationCD34+ cells isolated from cord blood were expanded in a hollow-fiber bioreactor using a novel cytokine cocktail at one-tenth the standard concentration using a MSC-free coating strategy.
-
![GettyImages-173543371-fluorescent-cells-microscopic]( "Rapid Automated Selection Of Mammalian Cell Colonies")
Rapid Automated Selection Of Mammalian Cell ColoniesDiscover how a new technology cultivates mammalian cells into clonal colonies and images them using fluorescent assays to isolate clonal cell populations based on surface protein expression.
-
![Esco downflow booth]( "Raise Your Standards With Downflow Booth Airflow Containment")
Raise Your Standards With Downflow Booth Airflow ContainmentEnsure personnel safety during hazardous material handling by mastering airflow dynamics and containment screens. Learn to achieve low exposure levels through advanced HEPA filtration methods.
-
![GettyImages-506999858-scientists-cell-culture-lab-development]( "Optimization And Scale-Up Of A Plasmid DNA Production Process")
Optimization And Scale-Up Of A Plasmid DNA Production ProcessOptimizing pDNA production in E. coli requires strategic media selection and scale-up planning. Explore a study that identifies ideal conditions for high-yield manufacturing.
-
![GettyImages-1067806062-scientist-lab-vaccine-vial]( "Quality Assurance In IVT RNA Vaccine Development Using Electrophoresis")
Quality Assurance In IVT RNA Vaccine Development Using ElectrophoresisDiscover advanced solutions for IVT RNA synthesis, focusing on enhancing fidelity in throughput, innovative technologies, and methodologies to optimize your RNA research and development processes.
NEWSLETTER ARCHIVE
- 05.15.26 -- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- 05.14.26 -- Discover critical components for fluid management and flow control
- 05.14.26 -- Early CDMO Engagement For Cell Therapies? CellProthera's CEO Thinks Not
- 05.13.26 -- Manufacturing Moves Shaping Advanced Therapies
- 05.13.26 -- How MTP Is Transforming Pharma Production Lines
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry
- Target Selection Drives The Future Of CAR T Therapy In Solid Tumors
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections
